首页 › 非小细胞肺癌 › 威斯康星州 › Green Bay
Green Bay WI 非小细胞肺癌临床试验
14项针对 非小细胞肺癌的研究正在 Green Bay及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
招募中3 期
- Bellin Memorial Hospital, Green Bay
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Bellin Memorial Hospital, Green Bay
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- 以及另外 4 项
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
招募中3 期
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls · 距离 25 英里
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
招募中3 期
- HSHS St. Vincent Hospital Regional Cancer Center, Green Bay
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
招募中3 期
- Aurora BayCare Medical Center, Green Bay
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
招募中2 期
- Aurora BayCare Medical Center, Green Bay
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
招募中3 期
- Research Site, Appleton · 距离 26 英里
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
招募中观察性研究
- ThedaCare Regional Cancer Center, Appleton · 距离 26 英里
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
招募中3 期
- Ascension Network - St Elizabeth's Hospital, Appleton · 距离 26 英里
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- Aurora BayCare Medical Center, Green Bay
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- Aurora BayCare Medical Center, Green Bay
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- Aurora BayCare Medical Center, Green Bay
- 以及另外 1 项
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
招募中观察性研究
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- Aurora BayCare Medical Center, Green Bay
- 以及另外 3 项
GEMINI-NSCLC: NSCLC Biomarker Study
招募中观察性研究
- ThedaCare Regional Cancer Center, Appleton · 距离 26 英里
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY121 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH57 项研究
- Washington, DC55 项研究
Green Bay的其他研究
- 肺癌12 项研究
- 结直肠癌10 项研究
- 急性髓系白血病8 项研究
- 结肠癌8 项研究
- 癌症（所有类型）7 项研究
- 乳腺癌7 项研究
- 头颈鳞状细胞癌7 项研究
- 胰腺癌6 项研究
- 膀胱癌6 项研究
- 黑色素瘤6 项研究
- 肾癌（肾细胞癌）6 项研究
- 前列腺癌6 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。